← Dashboard
Stock
LSBCF
LakeShore Biopharma Co., Ltd0 of 27 marquee funds currently hold3 CUSIPs mapped
Current holders
0
27 funds tracked
Ever held
2
Current + past
New this quarter
0
Exited this quarter
0
Marquee-fund ownership over time
Aug 14, 2024Nov 14, 2024May 15, 2025Nov 14, 2025
Now
0
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q2 2025 | Q4 2025 | — | +0% |
| D.E. Shaw | Q3 2024 | Q4 2025 | — | +0% |
Fundamentals
XBRL · LakeShore Biopharma Co., LtdAnnual figures sourced directly from LakeShore Biopharma Co., Ltd's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$85.67M
FY2025+6% YoY
Net income
-$13.93M
FY2025+77% YoY
EPS (diluted)
$-0.7300
FY2025-28% YoY
Free cash flow(?)
-$18.62M
FY2025+61% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for LakeShore Biopharma Co., Ltd. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 28, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERApr 29, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMar 25, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERFeb 6, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 29, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 20, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERNov 4, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERSep 22, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERSep 12, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERSep 10, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERAug 28, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERAug 18, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJul 31, 2025
- 20-FANNUAL REPORTJul 31, 2025
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJul 15, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2025 | Q4 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | Q4 2025 | $0.00 | — | +0% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.